STOCK TITAN
  1. Home
  2. Sec-filings
  3. LYEL
  4. [S-3] Lyell Immunopharma, Inc. Shelf Registration Statement

[S-3] Lyell Immunopharma, Inc. Shelf Registration Statement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-3
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock LYEL logo
Lyell Immunopharma, Inc.

NASDAQ:LYEL

LYEL Rankings

#5963 Ranked by Market Cap
N/A Ranked by Dividends

LYEL Latest News

Jun 23, 2025
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
Jun 17, 2025
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
Jun 9, 2025
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
Jun 4, 2025
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
May 13, 2025
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

LYEL Latest SEC Filings

Jun 26, 2025
[8-K] Lyell Immunopharma, Inc. Reports Material Event

LYEL Stock Data

144.67M
11.43M
13.73%
65.93%
2.77%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO